Sinclair IS Pharma rumoured to have received ‘friendly’ approach from Nestle
Sinclair IS Pharma, the London-based healthcare company, is believed to have received a “friendly” takeover approach from Switzerland-based food group Nestle, The Daily Mail reported. The market report said Sinclair, which has discovered an anti-ageing treatment to compete with Botox, would be a good fit for Nestle, after the Swiss group recently acquired North American rights to commercialise a number of Valeant Pharmaceuticals’ aesthetic dermatology products.
The report said Sinclair’s recent low share price has put the company onto the radar of cash-rich prospective buyers, and the business has been eyed by private-equity firms for some time.
AIM-listed Sinclair has a GBP 144m (EUR 177m) market cap.
Source Daily Mail